Results 141 to 150 of about 83,328 (323)

Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications. [PDF]

, 2019
The increasing number of patients with sequenced prostate cancer genomes enables us to study not only individual oncogenic mutations, but also capture the global burden of genomic alterations.
Bose, Rohit, Ryan, Matthew J
core   +1 more source

First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Journal of Clinical Oncology, 2019
PURPOSE CheckMate 568 is an open-label phase II trial that evaluated the efficacy and safety of nivolumab plus low-dose ipilimumab as first-line treatment of advanced/metastatic non–small-cell lung cancer (NSCLC).
N. Ready, M. Hellmann, M. Awad, G. Otterson, M. Gutierrez, J. Gainor, H. Borghaei, J. Jolivet, L. Horn, M. Mates, J. Brahmer, I. Rabinowitz, P. Reddy, J. Chesney, J. Orcutt, D. Spigel, M. Reck, K. O'Byrne, L. Paz-Ares, Wenhua Hu, K. Zerba, Xuemei Li, B. Lestini, W. Geese, J. Szustakowski, G. Green, Han Chang, S. Ramalingam   +27 more
semanticscholar   +1 more source

Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer

Alimentary Pharmacology &Therapeutics, EarlyView.
In a cohort of 1596 liver cancer patients with either current or prior HBV infection undergoing systemic therapy in Hong Kong, the risk of HBV reactivation during immune checkpoint inhibitor treatment was low when adequate antiviral prophylaxis was administered, irrespective of HBV infection status.
Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip   +9 more
wiley   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non–small cell lung cancer

, 2023
Hope Feldman, Boris Sepesi, Cheuk Hong Leung, Heather Lin, Annikka Weissferdt, Apar Pataer, William N. William, Garrett L. Walsh, David C. Rice, Jack A. Roth, Reza J. Mehran, Wayne L. Hofstetter, Mara B. Antonoff, Ravi Rajaram, Don L. Gibbons, J. Jack Lee, John V. Heymach, Ara A. Vaporciyan, Stephen G. Swisher, Tina Cascone   +19 more
openalex   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

FOXD3 Regulates VISTA Expression in Melanoma. [PDF]

, 2020
Immune checkpoint inhibitors have improved patient survival in melanoma, but the innate resistance of many patients necessitates the investigation of alternative immune targets.
Aplin, Andrew E., Berger, Adam C., Chervoneva,, Davies, Michael A., Erkes, Dan A., Fisher, David E., Gershenwald, Jeffrey E., Knecht, Meghan, Lo, Jennifer A., McCue, Peter A., Mollaee, Mehri, Purwin, Timothy J., Rosenbaum, Sheera R., Zhong, Zhijiu   +13 more
core   +1 more source

A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma [PDF]

, 2023
Rana R. McKay, Katharina Leucht, Wanling Xie, Opeyemi A. Jegede, David A. Braun, Michael B. Atkins, Marc‐Oliver Grimm, Toni K. Choueiri   +7 more
openalex   +1 more source

A Combinatorial Effect of Immune Checkpoint Inhibitors and CD40 Agonistic Antibody in Murine Pancreatic Cancer Model

Cancer Science, EarlyView.
We established and extensively analyzed an organoid‐based mouse model that closely mimics human pancreatic ductal adenocarcinoma. Monotherapy with an immune checkpoint inhibitor cocktail or a CD40 agonist antibody showed minimal efficacy. However, combining both reagents produced a strong synergistic effect by enhancing anti‐tumor immunity.
Juri Ichikawa, Hiroshi Okuda, Kuniyuki Kawano, Shingo Kato, Shinya Sato, Ryo Kuroishikawa, Daisuke Kurotaki, Wataru Kawase, Haruka Yoshida, Yukihiko Hiroshima, Itaru Endo, Shin Maeda, Tomohiko Tamura   +12 more
wiley   +1 more source

CNSC-03. NEURONAL INTERMEDIATE FILAMENT (NIF) ANTIBODY POSITIVE PARANEOPLASTIC SYNDROME IN A PATIENT WITH METASTATIC NEUROENDOCRINE PANCREATIC CARCINOMA AND TREATMENT WITH IPILIMUMAB/NIVOLUMAB [PDF]

, 2022
Karla Mora Rodriguez, Edwin Peguero, Yolanda Piña, Jonathan Strosberg, Neha Verma, Sepideh Mokhtari   +5 more
openalex   +1 more source